TRX-0237 mesylate (LMT-X; TRX0237; Leuco-MTx; LMTX; Hydromethylthionine mesylate), the mesylate salt of TRX 0237 which is currently in phase III clinical trials by TauRx, is a 2nd-generation tau protein aggregation and TDP-43 aggregation inhibitor with the potential for the treatment of Alzheimer's disease (AD) and frontotemporal dementia. It is a replacement formulation for Rember(R), the first company's first proprietary formulation of methylthioninium chloride (MTC). Both TRx 0237 and Rember are purified forms of Methylene Blue, an old drug that predates the FDA and is being widely used in Africa for the treatment for malaria, as well as for methemoglobinemia and other conditions. TRx 0237 and Rember share the same mode of action, but TRx 0237 has been designed as a stabilized, reduced form of MTC to improve the drug's absorption, bioavailability, and tolerability.

纯度：≥98%

CAS：1236208-20-0